Morphic Holding, Inc.
MORFDelisted Aug 16, 2024- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001679363
Morphic Holding, Inc. was delisted on Aug 16, 2024; its insiders filed their last Form 4 on Aug 21, 2024; 136 institutions reported holding it in 13F filings for Q2 2024, worth $1.54B in total; no superinvestor held it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Oct 8, 2026, 1:55 PM ET
Revenue flow, FY2023
Where the revenue went in FY2023, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.
Net loss for FY2023: $152.1M (29192.9% of revenue).
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 12, 2024 | Feb 23, 2023 | Feb 24, 2022 | Mar 1, 2021 | Feb 27, 2020 |
| Revenue | $521.0K | $70.8M | $19.8M | $44.9M | $17.0M |
| Research and development | $140.4M | $102.1M | $87.8M | $73.6M | $53.7M |
| Selling, general and administrative | $38.8M | $32.1M | $27.8M | $18.5M | $10.2M |
| Operating income | -$178.7M | -$63.4M | -$95.8M | -$47.2M | -$47.0M |
| Income tax | $380.0K | $67.0K | $0 | -$570.0K | $912.0K |
| Net income | -$152.1M | -$59.0M | -$95.5M | -$45.0M | -$43.3M |
| EPS, basic | $-3.59 | $-1.55 | $-2.67 | – | – |
| EPS, diluted | $-3.59 | $-1.55 | $-2.67 | – | – |
| Weighted shares, basic | 42.4M | 38.1M | 35.8M | – | – |
| Weighted shares, diluted | 42.4M | 38.1M | 35.8M | – | – |
| Margins and growth | |||||
| Operating margin | -34296.7% | -89.5% | -484.0% | -105.0% | -276.8% |
| Net margin | -29192.9% | -83.4% | -482.7% | -100.1% | -255.2% |
| Revenue growth, year over year | −99.3% | +257.7% | −56.0% | +164.7% | – |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 12, 2024 | Feb 23, 2023 | Feb 24, 2022 | Mar 1, 2021 | Feb 27, 2020 |
| Cash and equivalents | $58.6M | $59.3M | $171.4M | $102.0M | $101.6M |
| Accounts receivable | $0 | $455.0K | $2.31M | $7.31M | $3.47M |
| Total current assets | $716.9M | $362.2M | $418.3M | $239.4M | $243.6M |
| Property, plant and equipment | $2.77M | $2.12M | $2.58M | $2.61M | $3.45M |
| Total assets | $722.5M | $368.6M | $426.3M | $242.4M | $247.4M |
| Accounts payable | $7.70M | $3.48M | $4.80M | $3.85M | $5.17M |
| Total current liabilities | $24.8M | $17.1M | $38.3M | $39.4M | $35.4M |
| Total liabilities | $25.5M | $19.5M | $89.6M | $97.2M | $106.5M |
| Shareholders' equity | $697.0M | $349.1M | $336.7M | $145.2M | $140.9M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 12, 2024 | Feb 23, 2023 | Feb 24, 2022 | Mar 1, 2021 | Feb 27, 2020 |
| Operating cash flow | -$112.3M | -$101.0M | -$83.5M | -$46.0M | -$41.7M |
| Capital expenditures | $1.24M | $365.0K | $1.02M | $544.0K | $2.16M |
| Free cash flow | -$113.6M | -$101.3M | -$84.5M | -$46.5M | -$43.8M |
| Depreciation and amortization | $1.10M | $1.00M | $1.00M | $1.13M | $821.0K |
| Stock-based compensation | $40.9M | $29.0M | $21.2M | $11.1M | $3.53M |
| Investing cash flow | -$341.8M | -$56.5M | -$113.2M | $8.18M | -$136.0M |
| Financing cash flow | $453.4M | $45.3M | $266.3M | $38.3M | $93.3M |
| Net change in cash | -$695.0K | -$112.2M | $69.7M | $488.0K | -$84.3M |
| Ratio | |||||
| Stock-based compensation, % of revenue | 7858.5% | 41.0% | 107.0% | 24.6% | 20.8% |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Jul 23, 2024 | 50.2M | +4.8% | SEC |
| Apr 23, 2024 | 50.1M | +26.2% | SEC |
| Feb 20, 2024 | 50.0M | +26.6% | SEC |
| Oct 31, 2023 | 49.7M | +29.0% | SEC |
| Jul 31, 2023 | 47.9M | +24.5% | SEC |
| Apr 21, 2023 | 39.7M | +3.7% | SEC |
| Feb 21, 2023 | 39.5M | +6.6% | SEC |
| Oct 31, 2022 | 38.6M | +4.3% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.